Magnetic Resonance Imaging Pilot Study of Intravenous Glyburide in Traumatic Brain Injury

Howard M. Eisenberg,1 Martha E. Shenton,2,3 Ofer Pasternak,2 J. Marc Simard,1 David O. Okonkwo,4 Christina Aldrich,1 Feng He,5 Sonia Jain,5 and Erik G. Hayman1

Abstract

Pre-clinical studies of traumatic brain injury (TBI) show that glyburide reduces edema and hemorrhagic progression of contusions. We conducted a small Phase II, three-institution, randomized placebo-controlled trial of subjects with TBI to assess the safety and efficacy of intravenous (IV) glyburide. Twenty-eight subjects were randomized and underwent a 72-h infusion of IV glyburide or placebo, beginning within 10 h of trauma. Of the 28 subjects, 25 had Glasgow Coma Scale (GCS) scores of 6–10, and 14 had contusions. There were no differences in adverse events (AEs) or severe adverse events (ASEs) between groups. The magnetic resonance imaging (MRI) percent change at 72–168 h from screening/baseline was compared between the glyburide and placebo groups. Analysis of contusions (7 per group) showed that lesion volumes (hemorrhage plus edema) increased 1036% with placebo versus 136% with glyburide ($p = 0.15$), and that hemorrhage volumes increased 11.6% with placebo but decreased 29.6% with glyburide ($p = 0.62$). Three diffusion MRI measures of edema were quantified: mean diffusivity (MD), free water (FW), and tissue MD (MDt), corresponding to overall, extracellular, and intracellular water, respectively. The percent change with time for each measure was compared in lesions ($n = 14$) versus uninjured white matter ($n = 24$) in subjects receiving placebo ($n = 20$) or glyburide ($n = 18$). For placebo, the percent change in lesions for all three measures was significantly different compared with uninjured white matter (analysis of variance [ANOVA], $p < 0.02$), consistent with worsening of edema in untreated contusions. In contrast, for glyburide, the percent change in lesions for all three measures was not significantly different compared with uninjured white matter. Further study of IV glyburide in contusion TBI is warranted.

Keywords: contusion; edema; glyburide; MRI; SUR1; TBI

Introduction

More than 2 million Americans suffer injury or death due to traumatic brain injury (TBI) each year, with TBI being a major contributing factor in over one-third of trauma-related deaths.1 A significant proportion of brain trauma survivors experience long-term disability, resulting in large societal costs from both direct care as well as from loss of productivity by previously healthy individuals. However, despite decades of research, pharmacological therapy for TBI remains confined to early seizure prophylaxis and, possibly, barbiturates, based on a small trial showing better intracranial pressure (ICP) control compared with placebo.2 More than 30 controlled clinical trials of pharmacological therapies, however, have failed to improve mortality or outcome following TBI.3

TBI proceeds in two phases, an immediate primary injury to the brain due to structural disruption at the time of impact, and delayed, progressive injury that results from a variety of pathophysiological processes collectively termed secondary injury, including increasing edema and hemorrhagic progression of contusion.4–6 Recent research indicates a previously undescribed basis for some forms of post-traumatic secondary injury. Specifically, experimental models of contusion TBI,7–9 as well as patient-derived clinical samples,9,10 consistently demonstrate both upregulation and pathological pairing of sulfonylurea receptor 1 (SUR1) with the non-selective cation channel, transient receptor potential melastatin 4 (TRPM4), to form SUR1-TRPM4 channels in brain endothelium, astrocytes, and macrophages following contusion TBI.

Several pre-clinical studies provide a rationale for targeting SUR1 following contusion TBI. Inhibition of SUR1 using

1Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland.
2Departments of Psychiatry and Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.
3Department of Research and Development, VA Boston Healthcare System, Brockton Division, Brockton, Massachusetts.
4Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
5Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California.

© Howard M. Eisenberg et al., 2019. Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
glyburide or gene suppression reduces hemorrhagic progression and edema, and may be associated with functional improvements after contusion TBI, findings confirmed by several independent research groups.\textsuperscript{7–9,11} Similarly, glyburide reduces hemorrhagic progression after contusion injury to the spinal cord.\textsuperscript{12,13} Further, in patients with TBI, cerebrospinal fluid (CSF) levels of SUR1 may act as a biomarker that predicts swelling and outcome.\textsuperscript{14} Also, genetic studies of SUR1 and TRPM4 polymorphisms in TBI patients have identified several SUR1 and TRPM4 variants linked to brain swelling or cerebral edema.\textsuperscript{5–17}

Glyburide, a member of the sulfonylurea class of oral anti-diabetic drugs, is a potent pharmacological inhibitor of SUR1-TRPM4 channels.\textsuperscript{15} Recent clinical experience with intravenous (IV) glyburide in the treatment of large hemispheric infarction indicates that glyburide is well tolerated, without clinically significant off-target effects aside from occasional but manageable hypoglycemia.\textsuperscript{19,20} Clinical experience with glyburide treatment for TBI is limited to two small randomized controlled trials that used the oral form of the drug, and showed a probable benefit of glyburide with regard to contusion expansion and neurological outcome.\textsuperscript{51,22}

Here, we undertook a small Phase II multi-institutional randomized controlled trial to evaluate the safety and mitigation of hemorrhagic progression and edema with IV glyburide following TBI. Surrogate biomarkers derived from magnetic resonance imaging (MRI) were the primary outcome measures.

Methods

Study organization

This was a double-blind, randomized, placebo-controlled, Phase II trial of IV glyburide in patients with TBI (ClinicalTrials.gov identifier: NCT01454154). It was one of several clinical trials within the Department of Defense INTRuST [Injury &Traumatic Stress], Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium, but was the only consortium study focused on acute TBI. UCSD (University of California, San Diego) was the INTRuST coordinating center, providing the informatics and biostatistic scores. Remedy Pharmaceuticals, Inc. provided the drug (IV glyburide; a.k.a. RP-1127 or BIIB-093) and placebo (excipients) for the study, under an Investigational New Drug Application from the U.S. Food and Drug Administration. The study was supervised by the Institutional Review Boards of the individual centers, UCSD, and the USAMMCC (U.S. Army Medical Research and Materiel Command).

Analysis of the MRI data was conducted by the Psychiatry Neuroimaging Laboratory at Brigham and Women’s Hospital, Harvard Medical School, Department of Psychiatry, which was the core imaging center for the INTRuST consortium. The lead clinical center for this trial was UMSOM (University of Maryland School of Medicine), which later was joined by two other centers, UCSD and UPMC (University of Pittsburgh Medical Center), although ultimately, 76% of the total randomized participants were enrolled at UMSOM. The primary biostatistician (SJ) had full access to all the clinical data in the study. The project principal investigator (HME) had final responsibility for the decision to submit for publication.

Subject enrollment and randomization

The study protocol called for enrolling 100 participants into one of two arms, IV glyburide or placebo, at a 1:1 ratio. However, the coordinating center reduced the number of participating sites from five to three, and the study was terminated after 29 subjects had been randomized, 30 months after starting, due to slow enrollment and completion of the allotted period of funding. All participants’ legally authorized representatives (LARs) provided written informed consent at enrollment. Subjects were consented and enrolled into the study, but were not randomized until completion of the T1-weighted (T1w) and diffusion tensor imaging (DTI) sequences of the baseline MRI. Randomization and infusion of drug or placebo then proceeded, as long as infusion could be started within 10h of the trauma. Participants were randomly assigned to receive IV glyburide or placebo in a 1:1 ratio from a centralized, web-based randomization system (Interactive Web Randomization System). At randomization, subjects were stratified on the basis of their Glasgow Coma Scale (GCS) score (4–8 and 9–14) obtained free of the effects of sedating and/or paralytic drugs, closest to the time of randomization.

The major inclusion/exclusion criteria were age (18–75 years), GCS score 4–14, start of infusion within the 10-h window, history of treatment with sulfonylurea drugs, and perceived inability to tolerate the initial MRI scan (full inclusion/exclusion criteria are provided in Supplementary Appendix S1). The INTRuST coordinating center (except for the Biostatistics Core), Remedy Pharmaceuticals, the principal investigator, site investigators, patients, imaging core, and outcomes personnel were blinded to treatment.

Treatments

The bolus and the infusion concentrations of glyburide were both 5.3 μg/mL. Glyburide was infused IV as a loading dose, 0.13 mg over 2 min, then 0.16 mg/h for 6 h, and then 0.11 mg/h for 66 h (total daily dose on day 1 was 3.12 mg and on days 2 and 3 was 2.67 mg/day) versus placebo (similar in appearance to drug and at the same rate). This dose was based on data from a Phase I drug escalation safety study.\textsuperscript{23} The infusion protocol and 10-h window were identical to that used in a Phase II trial of glyburide in large hemispheric infarction.\textsuperscript{20} Drug vials, preparation bags, and tubing were identical in appearance for both treatment groups. Concomitant treatments followed national practice guidelines for TBI patients.\textsuperscript{24}

Study outcome measures

The pre-specified primary efficacy objective was to assess whether subjects treated with IV glyburide would show a decrease in MRI-defined edema and/or hemorrhage, compared with placebo-treated patients. The study protocol did not specify which specific measure of edema and/or hemorrhage would be primary (see below for the measures that were quantified). Efficacy outcome was assessed using data from two sequential MRIs, a baseline MRI before infusion of drug or placebo, and another MRI after completion of the infusion protocol then proceeded, as long as infusion could be started within 10h of the trauma. Participants were randomly assigned to receive IV glyburide or placebo in a 1:1 ratio from a centralized, web-based randomization system (Interactive Web Randomization System). At randomization, subjects were stratified on the basis of their Glasgow Coma Scale (GCS) score (4–8 and 9–14) obtained free of the effects of sedating and/or paralytic drugs, closest to the time of randomization.

The major inclusion/exclusion criteria were age (18–75 years), GCS score 4–14, start of infusion within the 10-h window, history of treatment with sulfonylurea drugs, and perceived inability to tolerate the initial MRI scan (full inclusion/exclusion criteria are provided in Supplementary Appendix S1). The INTRuST coordinating center (except for the Biostatistics Core), Remedy Pharmaceuticals, the principal investigator, site investigators, patients, imaging core, and outcomes personnel were blinded to treatment.

MRI data acquisition

MRI scans were acquired at each site on a 1.5T scanner. At UMSOM, two identical Siemens Avanto scanners were used
(baseline and follow-up scans for each subject were always on the same scanner). At the UCSD and UPMC sites, a single 1.5 Sigma GE scanner was used. One single phantom was used to standardize all scanners at all sites. Also, at each site, patients were always scanned using the same scanner.

The MRI acquisition was set to minimize differences between vendors and included anatomical sequences: high resolution (1 × 1 × 1 mm³) T1w (Siemens: magnetization-prepared rapid gradient-echo [MPRAGE], inversion time of 1100 msec, flip angle 7 degrees; GE: spoiled gradient recalled [SPGR], inversion time of 600 msec, flip angle 10 degrees), high resolution T2, proton density (Dual echo, echo time [TE]: 12 msec and 100 msec; 1 × 1 × 1 mm³), and a clinical fluid-attenuated inversion recovery (FLAIR) sequence (1.3 mm × 1 mm × 5 mm; inversion time: 2500 msec). Two additional scans of interest were diffusion MRI and susceptibility-weighted imaging (SWI). The diffusion MRI scan included a multi-shell design with 46 unique gradient orientations and a total of 66 volumes spread over 5 nested b-shells of 1 shell design with 46 unique gradient orientations and a total of 66 weighted imaging (SWI). The diffusion MRI scan was a 3D gradient-echo scan (1 mm × 1 mm × 1.5 mm, TR/TE 50/40 msec, flip angle: 15 degrees) outputting the magnitude and phase images.

**Regions of interest**

Three regions of interest (ROIs) were analyzed for volumetric changes: the total lesion volume (blood plus edema) (n = 15), blood alone (n = 14), and the total brain volume (n = 24). Four additional ROIs were analyzed for changes in edema: uninjured white matter (n = 24); lesions, that is, contusions (n = 14); all quadrants in a coronal slice (four per subject; n = 96); and the maximally affected quadrant (one per subject; n = 24). For lesion ROIs (blood plus edema), we aligned images from computed tomography (CT) and MRI. Lesion volumes were calculated by electronically tracing the areas of the lesion on sequential slices. Edema was identified predominantly based on hyperintensities in the FLAIR and T2 sequences (Fig. 1A). Hemorrhage was identified based on hypointensities in the SWI contrast (following phase enhancement) and blood densities on CT (Fig. 2A,B). The final lesion ROIs were reviewed and modified by a neurosurgeon, a neuroradiologist, and a researcher specializing in image analysis, blinded to treatment arm. Lesions were excluded if they were outside brain (e.g., subarachnoid and extra-axial and interventricular hemorrhages were excluded). Apparent lesions also were excluded if they were directly related to a treatment that took place between the two MRIs (e.g., surgery or insertion of an intraventricular catheter).

For uninjured white matter ROIs, which were intended as an exploratory approach to identify global effects of the drug, we used expectation-maximization (EM) segmentation of the T1w image (FAST; FSL) (Fig. 1C). The white matter segment was eroded by one voxel to avoid partial volume voxels, and we excluded all lesions that were defined in the previous approach (the lesion segments here were first dilated by one voxel).

For all quadrant ROIs, which also were intended as an exploratory approach to identify global effects of the drug, each quadrant within a coronal brain slice was studied separately, whether or not a lesion was present (Fig. 1B).

For the maximally affected quadrant, the single quadrant of a coronal brain slice with the maximal change in edema parameters for each subject was used.

**MRI data analysis**

All evaluators and those involved in management of subjects including the PI (HME) were blinded to treatment arm and other clinical or demographic information. All imaging data were subjected to visual quality control to exclude images with severe motion or other artifacts. The diffusion data were manually masked to exclude non-brain areas. The anatomical images were co-registered using rigid transformations (within time-points) and affine transformations (between time-points). In addition, the anatomical images were manually masked based on the T1w image, all by investigators blind to treatment arm.

The diffusion MRI data were pre-processed using motion and eddy correction applied by means of affine transformations (FLIRT; FSL). The aligned images then were analyzed using the DTI model, and the free-water imaging model, yielding voxel-wise maps of DTI measures and free-water imaging measures.

Three MRI diffusion measures were used to assess edema: (1) mean diffusivity (MD); (2) the volume fraction of free water (FW); and (3) tissue mean diffusivity (MDt). MD was derived from the DTI, whereas FW and MDt were derived from the free-water imaging model. MD provides an overall measure of diffusivity; as...
water molecules move faster on average, the MD measure is higher. FW and MDt measures further deconstruct the signal contribution into extracellular (FW) and intracellular (MDt) water. The free-water model separates the signal into water molecules that are free to diffuse in the extracellular space (i.e., diffusing at $3 \times 10^{-3}$ mm$^2$ sec$^{-1}$), and all remaining molecules that are restricted or hindered by membranes and other tissue-related obstacles.

Higher fractions of extracellular space, which are expected in vasogenic edema, would increase FW. Changes in the geometry, and hence the speed of water molecules in proximity to tissue, would affect the MDt, whereas less restricted motion would increase MDt. On the other hand, cellular swelling (i.e., cytotoxic edema) would decrease the non-restricted space, decreasing FW, and modifying MDt. Values for MD, FW, and MDt were averaged for each of the four ROIs described above. Because edema was an important end-point due to the expected drug mechanism, and because the ROIs were large, we did not consider anisotropic measures such as fractional anisotropy or radial or axial diffusivities. Hemorrhage was assessed by the number of positive voxels on SWI within the boundaries of the lesion ROIs.

**Sample size calculation**

A sample size calculation was performed based on a two-sided, two-sample $t$ test to compare published differences in absolute values in apparent diffusion coefficient (ADC) in TBI patients relative to normal subjects, and was computed using standardized effect sizes. With an anticipated sample size of 100 participants (equal allocation between active and placebo arms), the study would have 80% power to detect a 60% standardized change in treatment arms, assuming 10% attrition over 72 h and $\alpha=0.05$.

**Statistical analysis plan**

Analyses were to incorporate the intent-to-treat principle, namely, all randomized participants would be included in the analysis according to their treatment assigned at randomization. The safety analysis was to be performed on the safety population only, that is, all those who were exposed to any study drug. No adjustments for multiple comparisons were to be made for secondary analyses, and a $p$-value of 0.05 was to be considered statistically significant. The final statistical analysis plan was to be determined by the INTRuST Biostatistics Core within 6 months before study end.

**Statistical analysis**

All MRI measures were evaluated as the “percent change” of the second MRI compared with the screening/baseline MRI, before infusion of study drug or placebo. Summary measures (mean, standard deviation, median, first and third quartiles, minimum and maximum values) described the data overall and by study arm for each outcome at screening/baseline and at the second scan. Summary measures were produced overall and by study arm for each outcome for the percent change from screening/baseline to the second scan. The primary analysis was based on a two-sided, two-sample Wilcoxon rank sum test to compare the glyburide and placebo arms. A secondary analysis of the three MRI measures of edema (MD, FW and MDt) was based on an analysis of variance (ANOVA) to compare four groups: lesions versus uninjured white matter, in the glyburide and placebo arms. Safety data were summarized overall and by treatment groups. Fisher’s exact test was used to compare the number of subjects between groups who experienced any adverse events (AEs). Statistical analyses were performed in R version 3.1.1. (www.r-project.org) or GraphPad Prism version 8.

**Results**

**General**

In all, 1483 potentially qualified participants were screened at the three centers, the largest number at UMSOM (924). Of those screened, 38 were consented. The most frequent reasons not to consent included: GCS score out of range (529), perceived inadequate time from admission to hospital to start of infusion (202), and LAR not available (95). Other less common reasons included an anticoagulant medication and elevated blood alcohol (see Supplementary Fig. S1). Of the 38 consented, 9 could not be randomized (5 could not complete the baseline MRI and 4 could not start the infusion on time). Of the 29 subjects randomized (15 in the glyburide group, 14 in the placebo group), 1 randomized to the IV glyburide arm did not receive the drug because of withdrawal of consent. Two subjects were randomized or infused incorrectly. Errors included randomization or infusion outside of the time window, and protocol-unspecified stopping and restarting of infusion. These protocol violations occurred early in the trial. These subjects were included in the efficacy and safety analysis, due to the intent-to-treat design. However, data from these subjects were not included when reporting details about infusion and completing infusion according to protocol. Thus, 28 participants completed the acute phase of the study and reached their primary end-points. All 26 uncensored participants had the 72-h infusion of the study drug beginning within 10 h of injury.
Baseline characteristics

Seventy-two percent of the randomized participants were male, 10 in the placebo arm and 11 in the glyburide arm, and 28% were female (4 in each arm). The median age in the placebo arm was 23 years (66 maximum) and it was 22 years in the glyburide arm (60 maximum). ICP was monitored at randomization in 20 participants. The median ICP at randomization was 14 mm Hg in the placebo arm (maximum 19) and 11 mm Hg in the glyburide arm (maximum 16). Randomization median P_{O2} and mean arterial pressure were virtually identical in the two arms and were within normal ranges. Randomization median blood glucose was 138 mg/dL (185 maximum) in the placebo arm and 139 mg/dL (maximum 248) in the glyburide arm.

GCS scores obtained at the time closest to randomization are shown in Table 1. No patient with a GCS score >11 met requirements for randomization. Twenty-five of the 29 randomized participants had GCS scores 6–10, 86% of the cohort. A GCS score of 7 was the most common score. In this regard, the cohort was in the range of lower-moderate to upper-severe injury.

Laboratory findings

Routine blood chemistries were collected at screening, baseline, and at days 1, 2, 3, and 4. There were no group differences with regard to most of these measures. Glucose was monitored; blood samples were taken hourly for the first 24 h, then every 4 h for the next 24 h. Hypoglycemia was managed by a detailed protocol (see Supplementary Appendix S2), which specified glucose levels, and specified administering glucose and, if necessary, reducing or suspending the infusion of the study drug (investigator blind to treatment arm). Two participants had glucose levels <55 mg/dL at one time-point. None of the 26 uncensored subjects had suspension of drug infusion; all cases of hypoglycemia were managed by infusion of glucose. The glucose data were analyzed using an area under the curve (AUC) approach by 24 h. No significant difference between groups was found. Hourly collection of vital signs, which included blood pressure and heart rate, were also analyzed using AUC by 24 h, with no significant differences found between groups.

Adverse events

There were no deaths. Three patients (in the glyburide arm, 1 in the placebo arm) had transient neurological worsening (decreased GCS score of 2 points in 2 consecutive h and/or a newly dilated pupil). There were no significant differences in the frequencies of defined AEs between the two treatment groups (glyburide, 87% vs. placebo, 100%; p=0.48), nor was there a significant difference with regard to severe adverse events (SAEs) (glyburide, 20% vs. placebo, 14%; p=0.99). Overall, there were 7 SAEs in 5 participants (Table 2).

MRI analysis—general

Of the 26 uncensored participants, all had a 72-h drug infusion beginning within 10 h of trauma. Of the 28 participants randomized and infused, 17 had their second scan within the initially proposed 72±12-h window (drug 8, placebo 9), whereas 7 additional participants had their second scan at or before 168 h (drug 3, placebo 4). Four others did not have a second scan within the 168-h window. For the 14 participants with identified lesions (contusions), 10 participants had their second scan within the 72±12-h interval (drug 5, placebo 5). The other 4 had their second scan at or before 168 h (drug 2, placebo 2). The distribution of randomization GCS for the lesion ROI cohort is shown in Table 3.

MRI analysis—volumetric changes

Three ROIs were analyzed for volumetric changes: the total lesion volume (blood plus edema), the volume of blood alone, and the total brain volume (Table 4). Lesion volumes increased in both treatment arms, but more so in the placebo arm. The volume of blood in lesions increased in the placebo arm, whereas it decreased in the glyburide arm (Fig. 2A,B). Neither of these differences reached statistical significance. Changes in total brain volume were small.

MRI analysis—measures of edema in four ROIs

The percent change from screening/baseline to the second scan was analyzed for three measures of edema: MD (overall water), FW (extracellular water) and MD_{t} (intracellular water); these three measures of edema were evaluated in four ROIs: uninjured white matter, lesions, all quadrants, and the maximally affected quadrant.

Table 1. Glasgow Coma Scale Score at Randomization

| GCS  | Placebo | Glyburide | Total |
|------|---------|-----------|-------|
| 4    | 0 (0%)  | 1 (6.7%)  | 1 (3.4%) |
| 5    | 1 (7.1%)| 1 (6.7%)  | 2 (6.9%) |
| 6    | 2 (14.3%)| 2 (13.3%)| 4 (13.8%) |
| 7    | 5 (35.7%)| 5 (33.3%)| 10 (34.5%) |
| 8    | 2 (14.3%)| 1 (6.7%)  | 3 (10.3%) |
| 9    | 1 (7.1%)| 3 (20%)   | 4 (13.8%) |
| 10   | 2 (14.3%)| 2 (13.3%)| 4 (13.8%) |
| 11   | 1 (7.1%)| 0 (0%)    | 1 (3.5%) |
| Total| 14 (100%)| 15 (100%)| 29 (100%) |

GCS, Glasgow Coma Scale.
in each subject (Table 5). Overall, the greatest differences between treatment arms was found in lesion ROIs, in which all three measures of edema showed larger percent increases with placebo compared with glyburide. In pairwise comparisons, only MDt in the all-quadrants ROI reached statistical significance between glyburide and placebo.

We performed a secondary analysis of the three measures of edema, comparing changes in uninjured white matter and in lesions in the two treatment arms (Fig. 3). ANOVA showed a significant difference in all three measures of edema \( (p<0.02) \). Post hoc comparisons showed no significant effect of drug in uninjured white matter or in lesions, as in the primary pairwise analyses. However, comparing the placebo arms, there was a significant difference between uninjured white matter and lesions in all three measures of edema, consistent with worsening of edema with time in untreated contusions. By contrast, comparing the glyburide arms, there was no significant difference between uninjured white matter and lesions for any of the three measures of edema.

### Clinical outcomes

As judged by the GOS-E at 90 days, half of the patients in the glyburide group made a good recovery, although 3 were categorized as either vegetative or severely disabled (Table 6). Dichotomizing for GOS-E \( \leq 4 \) versus \( >4 \) at 90 days showed no significant difference between groups \( (p=0.32) \).

### Discussion

We sought to assess two principal aspects of glyburide therapy in TBI, namely whether glyburide can be safely administered early after moderate-to-severe TBI, and whether glyburide ameliorates secondary injury, specifically, the development of edema and the delayed expansion of hemorrhage.

The severity of injury in the subjects reported here—moderate (GCS 9–12) and the better end of severe (GCS 6–8) injury, with a few sustaining severe polytrauma—was likely influenced by multiple factors, including the time for transfer from the scene, resuscitation, obtaining consent from a LAR, and the requirement for early MRI, which together caused many screened patients not to be randomized. No patient with GCS \( >11 \) met requirements for randomization, which may reflect the fact that patients with lesser injuries are unlikely to be transferred to the R. Adams Cowley Shock Trauma Center at the University of Maryland, where most patients were recruited.

The cohorts, glyburide and placebo, reported here were small, but they were well balanced with regard to important predictors, including randomization GCS, age, and ICP in the overall, as well as in the lesion ROI subset. They also were balanced as to the time the second MRI was acquired, at 72 h or later. There were no important differences in the baseline physiological data of blood pressure, glucose, or ICP as analyzed by AUC.

No safety concerns were reported. Only two subjects required correction of asymptomatic hypoglycemia by infusion of glucose, and drug infusion did not have to be stopped in any subject. With TBI hypoglycemia may be detrimental to neurological recovery due to increased demands of brain energy metabolism. However, patients treated with glyburide demonstrated glucose levels comparable to those of controls. Studies of IV glyburide in ischemic stroke \(^{19,20} \) have found a similar absence of symptomatic hypoglycemia. This small trial indicates that early use of IV glyburide in moderate-to-severe TBI may be safe, provided that blood glucose is closely monitored and properly managed.

MRI parameters for edema and blood indicated that glyburide may be useful in contusion TBI. Statistical significance was elusive in pairwise comparisons, likely due to the small cohorts, especially with contusions (7 per group), combined with the large variance that is typical in studies of TBI. Nevertheless, interesting observations were made. The increase in lesion volume (hemorrhage plus edema) over time was many-fold greater in placebo compared with glyburide-treated subjects, and the blood volume increased in placebo-treated subjects, whereas it decreased in glyburide-treated subjects. Notably, an analysis comparing uninjured white matter versus lesions showed that in placebo-treated subjects, measures of edema increased significantly with time, whereas they did not in glyburide-treated subjects. Together, our findings provide preliminary evidence of a favorable effect of glyburide in human TBI that mirrors pre-clinical findings. \(^{7–9} \) The absence of a significant effect,

---

**Table 4. Percent Changes in Three Volumes That Were Analyzed**

| Volume                          | Mean   | SD     | N  | P   |
|--------------------------------|--------|--------|----|-----|
| Total lesion (blood + edema)   | G 136.06 | 195.62 | 7  | 0.15|
| Blood alone                    | G –29.55 | 36.75  | 7  | 0.62|
| Total brain                    | G 2.01  | 9.02   | 11 | 0.13|

G, glyburide; P, placebo; SD, standard deviation.

**Table 5. Percent Changes in Three MRI Measures of Edema in Four Regions of Interest**

| Region of interest | Measure of edema | Treatment | Mean   | SD     | N  | P   |
|--------------------|------------------|----------|--------|--------|----|-----|
| Uninjured white matter | MD 3.95 | 6.40   | 11  | 0.49  |
|                    | P 1.55          | 3.14   | 7    | 0.15  |
|                    | FW 11.74        | 17.36  | 11  | 0.28  |
|                    | P 3.24          | 7.84   | 13   |       |
| Lesions            | MD 6.27         | 9.21   | 7    | 0.26  |
|                    | P 22.04         | 23.94  | 7    |       |
|                    | FW 10.73        | 13.99  | 7    | 0.32  |
|                    | P 44.96         | 57.68  | 7    |       |
|                    | MDt 2.41        | 6.67   | 7    | 0.21  |
|                    | P 9.66          | 8.31   | 7    |       |
| All quadrants      | MD 3.20         | 5.94   | 44  | 0.48  |
|                    | P 3.71          | 5.13   | 52   |       |
|                    | FW 12.44        | 15.25  | 44  | 0.42  |
|                    | P 10.20         | 15.80  | 52   |       |
|                    | MDt 0.68        | 3.10   | 44  | 0.05  |
|                    | P 1.33          | 2.04   | 52   |       |
| Maximally affected | MD 6.37         | 6.96   | 11  | 0.95  |
| quadrant           | P 6.81          | 7.27   | 13   |       |
|                    | FW 20.29        | 16.95  | 11  | 0.49  |
|                    | P 16.98         | 22.69  | 13   |       |
|                    | MDt 2.36        | 3.53   | 11  | 0.36  |
|                    | P 2.90          | 3.23   | 13   |       |

FW, free water; G, glyburide; MD, mean diffusivity; MDt, tissue mean diffusivity; MRI, magnetic resonance imaging; P, placebo; SD, standard deviation.
on clinical outcome was not unexpected, given the small sample size and the potential for multiple confounders.

Given the pre-clinical evidence showing an effect of glyburide on hemorrhagic progression of contusion,7–9 we hypothesized that glyburide administration would reduce hemorrhagic expansion. In the literature on contusion TBI, hemorrhagic expansion is observed in ~50% of cases5,6 whereas in this small study, no subjects exhibited frank hemorrhagic expansion. Importantly, albeit unexpectedly, glyburide-treated subjects demonstrated a marked decrease in hemorrhage volume, whereas a small increase was observed with placebo. The observed decrease in hemorrhage volume is not readily accounted for solely by a reduction in expansion. Although speculative, the observed reduction may derive from an effect of glyburide on macrophages, which play a key role in hemorrhage resorption.31–33 Macrophages that are present within hemorrhagic contusions are known to upregulate SUR1-TRPM4,9 and macrophage phagocytic activity is reportedly enhanced by glyburide.34,35

There are several limitations of this trial. First, the trial included only 28 participants. Second, the study population was heterogeneous in that only half (14/28) had contusions, the type of injury in which an effect of glyburide may be the most anticipated. Third, the timing of follow-up MRI was heterogeneous, potentially limiting the interpretation of the effects of IV glyburide. Fourth, the drug

**Table 6. GOS-E at 90 Days**

|                      | Glyburide | Placebo |
|----------------------|-----------|---------|
| Dead                 | 0 (0%)    | 0 (0%)  |
| Vegetative state (VS)| 2 (16.67%)| 0 (0%)  |
| Lower severe disability (Lower SD) | 1 (8.33%) | 0 (0%) |
| Upper severe disability | 0 (0%)    | 1 (7.69%) |
| Lower moderate disability (Lower MD) | 2 (16.67%) | 1 (7.69%) |
| Upper moderate disability (Upper MD) | 1 (8.33%) | 7 (53.85%) |
| Lower good recovery (Lower GR) | 3 (25%)    | 4 (30.77%) |
| Upper good recovery (Upper GR) | 3 (25%)     | 0 (0%)  |

GOS-E, Glasgow Outcome Scale Extended.
was started nearly 10 h after trauma. In light of the time and efficacy interaction of glyburide in pre-clinical TBI studies, this comparatively late administration may have attenuated the observed effect size. Fifth and finally, it is possible that a higher dose of IV glyburide than that used in this study might have led to a more robust clinical effect. Further study is needed to confirm the results reported here that glyburide may ameliorate both edema and hemorrhagic progression in moderate-to-severe contusion TBI.

Acknowledgments

We extend our thanks to patients and their families who participated in this trial for the purpose of advancing research in TBI.

Funding Statement

This study was funded by a grant to HME from the Department of Defense U.S. Army Medical Research and Materiel Command (W81XWH-08-2-0159), INTRuST, and by Remedy Pharmaceuticals, Inc.

Author Disclosure Statement

JMS holds a U.S. patent (7,285,574), “A novel non-selective cation channel in neural cells and methods for treating brain swelling.” JMS is a member of the Board of Directors and holds shares in Remedy Pharmaceuticals, Inc. and is a paid consultant for Biogen. For all other authors, no competing financial interests exist.

Supplementary Material

Supplementary Figure S1
Supplementary Appendix S1
Supplementary Appendix S2

References

1. Centers for Disease Control and Prevention. (2013). CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb. Mortal. Wkly. Rep. 62, 549–552.
2. Eisenberg, H.M., Frankowski, R.F., Contant, C.F., Marshall, L.F., and Walker, M.D. (1988). High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J. Neurosurg. 69, 15–23.
3. Loane, D.J., and Faden, A.I. (2010). Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol. Sci. 31, 596–604.
4. Cepeda, S., Gomez, P.A., Castano-Leon, A.M., Martinez-Perez, R., Munarriz, P.M., and Lagares, A. (2015). Traumatic intracerebral hemorrhage: risk factors associated with progression. J. Neurotrauma 32, 1246–1253.
5. Carnevale, J.A., Segar, D.J., Powers, A.Y., Shah, M., Doberstein, C., Drapcho, B., Morrison, J.F., Williams, J.R., Collins, S., Monteiro, K., and Asaad, W.F. (2016) Blossoming contusions: identifying factors contributing to the expansion of traumatic intracerebral hemorrhage. J. Neurosurg. 129, 1305–1316.
6. Wilkes, S., McCormack, E., Kenney, K., Stephens, B., Passo, R., Harburg, L., Silverman, E., Moore, C., Bogoslovsky, T., Pham, D., and Diaz-Arrastia, R. (2018). Evolution of traumatic parenchymal intracranial hematomas (ICHs): comparison of hematoma and edema components. Front. Neurol. 9, 527.
7. Simard, J.M., Kilbourne, M., Tsyshbulyak, O., Tosun, C., Caridi, J., Ivanova, S., Keledjian, K., Bochicchio, G., and Gerzanich, V. (2009). Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J. Neurotrauma 26, 2257–2267.
8. Zweckberger, K., Hackenberg, K., Jung, C.S., Hentle, D.N., Kiening, K.L., Unterberg, A.W., and Sakowitz, O.W. (2014). Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience 272, 199–206.
9. Gerzanich, V., Stokum, J.A., Ivanova, S., Woo, S.K., Tsyshbulyak, O., Sharma, A., Akkentli, F., Imran, Z., Aarabi, B., Sahauquillo, I., and Simard, J.M. (2018). Sulfonylurea receptor 1, transient receptor potential cation channel subfamily M member 4, and KIR6.2 role in hemorrhagic progression of contusion. J. Neurotrauma. 36, 1060–1079.
10. Martinez-Valverde, T., Vidal-Jorge, M., Martinez-Saez, E., Castro, L., Arikan, F., Cordero, E., Radoi, A., Poca, M.A., Simard, J.M., and Sahauquillo, I. (2015). Sulfonylurea receptor 1 in humans with post-traumatic brain contusions. J. Neurotrauma 32, 1478–1487.
11. Xu, Z.M., Yuan, F., Liu, Y.L., Ding, J., and Tian, H.L. (2017). Glibenclamide attenuates blood-brain barrier disruption in adult mice after traumatic brain injury. J. Neurotrauma 34, 925–933.
12. Simard, J.M., Tsyshbulyak, O., Ivanov, A., Ivanova, S., Bhatta, S., Geng, Z., Woo, S.K., and Gerzanich, V. (2007). Endothelial sulfonylurea receptor 1-regulated NC(Ca-ATP) channels mediate progressive hemorrhagic necrosis following spinal cord injury. J. Clin. Invest. 117, 2105–2113.
13. Simard, J.M., Woo, S.K., Norenberg, M.D., Tosun, C., Chen, Z., Ivanova, S., Tsyshbulyak, O., Bryan, J., Landsman, D., and Gerzanich, V. (2010). Brief suppression of ABCB1 prevents autodestruction of spinal cord after trauma. Sci. Transl. Med. 2, 28ra29.
14. Jha, R.M., Puccio, A.M., Chou, S.H., Chang, C.H., Wallisch, J.S., Molyneaux, B.J., Zusman, B.E., Shutter, L.A., Poloyac, S.M., Janesko-Feldman, K.L., Okonkwo, D.O., and Kochanek, P.M. (2017). Sulfonylurea receptor 1: a novel biomarker for cerebral edema in severe traumatic brain injury. Crit. Care Med. 45, e255–e264.
15. Jha, R.M., Puccio, A.M., Okonkwo, D.O., Zusman, B.E., Park, S.Y., Wallisch, J., Empey, P.E., Shutter, L.A., Clark, R.S., Kochanek, P.M., and Conley, Y.P. (2017). ABCB1 single nucleotide polymorphisms are associated with cerebral edema in severe TBI. Neurocrit. Care 26, 213–224.
16. Jha, R.M., Desai, S.M., Zusman, B.E., Koleck, T.A., Puccio, A.M., Okonkwo, D.O., Park, S.Y., Zusman, B.E., Clark, R.S.B., Shutter, L.A., Wallisch, J.S., Empey, P.E., Kochanek, P.M., and Conley, Y.P. (2018). Downstream TRPM4 polymorphisms are associated with intracranial hypertension and statistically interact with ABCB1 single nucleotide polymorphisms in a prospective cohort of severe traumatic brain injury. J. Neurotrauma 36, 1804–1817.
17. Jha, R.M., Koleck, T.A., Puccio, A.M., Okonkwo, D.O., Park, S.Y., Zusman, B.E., Clark, R.S.B., Shutter, L.A., Wallisch, J.S., Empey, P.E., Kochanek, P.M., and Conley, Y.P. (2018). Regionally clustered ABCB1 polymorphisms in a prospective cohort predict cerebral edema and outcome in severe traumatic brain injury. J. Neurourosurg. Psychiatry 89, 1152–1162.
18. Simard, J.M., Chen, M., Tarasov, K.V., Bhatta, S., Ivanova, S., Melnychenko, L., Tsyshbulyak, N., West, G.A., and Gerzanich, V. (2006). Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat. Med. 12, 433–440.
19. Sheth, K.N., Kimberly, W.T., Elm, J.J., Kent, T.A., Mandava, P., Yoo, A.J., Thomalla, G., Campbell, B., Donnan, G.A., Davis, S.M., Albers, G.W., Jacobson, S., Simard, J.M., and Stern, B.J. (2014). Pilot study of intravenous glibenclamide in patients with a large ischemic stroke. Stroke 45, 281–285.
20. Sheth, K.N., Elm, J.J., Molyneaux, B.J., Hinson, H., Beslow, L.A., Sze, G.K., Ostwaldt, A.C., Del Zoppo, G.J., Simard, J.M., Jacobson, S., and Kimberly, W.T. (2016). Safety and efficacy of intravenous glibenclamide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 15, 1160–1169.
21. Zafarroost, P., Ghasemi, A.A., Salehpour, F., Piroti, C., and Ziaiee, E. (2016). Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma. Trauma Mon. 21, e25113.
22. Khalili, H., Derakhshan, N., Niakan, A., Ghaffarpasand, F., Salehi, M., Eshraghian, H., Shakhlabard, A., and Zahabi, B. (2017). Effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries: a randomised double-blind placebo-controlled clinical trial. World Neurosurg. 101, 130–136.
23. Simard, J.M., Sheth, K.N., Kimberly, W.T., Stern, B.J., del Zoppo, G.J., Jacobson, S., and Gerzanich, V. (2014). Glibenclamide in cerebral ischemia and stroke. Neurocrit. Care 20, 319–323.
24. Carney, N., Totten, A.M., O’Reilly, C., Ullman, J.S., Hawryluk, G.W., Bell, M.J., Bratton, S.L., Chesnut, R., Harris, O.A., Kissoon, N., Rubiano, A.M., Shutter, L., Tasker, R.C., Vavilala, M.S., Wilberger, J., Wright, D.W., and Ghajar, J. (2017). Guidelines for the Management of Severe Traumatic Brain Injury, fourth edition. Neurosurgery 80, 6–15.
25. Haacke, E.M., Xu, Y., Cheng, Y.C., and Reichenbach, J.R. (2004). Susceptibility weighted imaging (SWI). Magn. Reson. Med. 52, 612–618.
26. Basser, P.J., Mattiello, J., and LeBihan, D. (1994). MR diffusion tensor spectroscopy and imaging. Biophys. J66, 259–267.
27. Pierpaoli, C., Jezzard, P., Basser, P.J., Barnett, A., and Di Chiro, G. (1996). Diffusion tensor MR imaging of the human brain. Radiology 201, 637–648.
28. Assaf, Y., and Pasternak, O. (2008). Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J. Mol. Neurosci. 34, 51–61.
29. Pasternak, O., Sochen, N., Gur, Y., Intrator, N., and Assaf, Y. (2009). Free water elimination and mapping from diffusion MRI. Magn. Reson. Med. 62, 717–730.
30. Meier, R., Bechir, M., Ludwig, S., Sommerfeld, J., Keel, M., Steiger, P., Stocker, R., and Stover, J.F. (2008). Differential temporal profile of lowered blood glucose levels (3.5 to 6.5 mmol/l versus 5 to 8 mmol/l) in patients with severe traumatic brain injury. Crit. Care 12, R98.
31. Zhao, X., Grotta, J., Gonzales, N., and Aronowski, J. (2009). Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke 40, 922–94.
32. Wang, G., Zhang, J., Hu, X., Zhang, L., Mao, L., Jiang, X., Liou, A.K., Leak, R.K., Gao, Y., and Chen, J. (2013). Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J. Cereb. Blood Flow Metab. 33, 1864–1874.
33. Zhao, X., Sun, G., Ting, S.M., Song, S., Zhang, J., Edwards, N.J., and Aronowski, J. (2015). Cleaning up after ICH: the role of Nrf2 in modulating microglia function and hematoma clearance. J. Neurochem. 133, 144–152.
34. Ortega, F.J., Gimeno-Bayon, J., Espinosa-Parrilla, J.F., Carrasco, J.L., Batlle, M., Pugliese, M., Mahy, N., and Rodriguez, M.J. (2012). ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Exp. Neurol. 235, 282–296.
35. Redondo-Castro, E., Hernandez, J., Mahy, N., and Navarro, X. (2013). Phagocytic microglial phenotype induced by glibenclamide improves functional recovery but worsens hyperalgesia after spinal cord injury in adult rats. Eur. J. Neurosci. 38, 3786–3798.

Address correspondence to:
Howard M. Eisenberg, MD
University of Maryland School of Medicine
22 South Greene Street, Suite S12D
Baltimore, MD 21201-1595

E-mail: HEisenberg@som.umaryland.edu